From: Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
Assay | Test principle | Cells | Incubation time (h) | Reference substance | Max. Conc. (μg/ml) | Min. Conc. (μg/ml) |
---|---|---|---|---|---|---|
WST-1 | Cell viability | HUVEC | 24 | Paclitaxel | 50,000 | 625 |
BrdU | Cell proliferation | HUVEC | 24 | Paclitaxel | 50,000 | 625 |
Matrigel Angiogenese | Tube Formation 2D | HUVEC | 24 | Untreated cells | 829 | 13 |
Spheroid-based Cellular 3D Angiogenesis | Tube Formation 3D | HUVEC | 24 | Sunitinib | 20,000 | 20 |
Alamar Blue | Cell viability 2D | Tumor cells | 72 | Actinomycin-D | 10,000 | 3.33 |
Soft Agar | Cell viability 3D | Tumor cells | 216–288 | Actinomycin-D | 10,000 | 3.33 |
Oris™ | Cell migration and invasion | Tumor cells | 24–48 | SKI-606 (Bosutinib) | 1000 | 600 |